As a diabetes educator and pharmacist, I have had a lot of success helping patients improve their diabetes care. But at the end of the day, I get to go home diabetes free. This week, one of my pals and a pharmacist educator is sharing his professional and personal opinions …

Female, 32 years of age, type 1 diabetes, presented with Stage II partial thickness ulcer between 1st and 2nd toe R foot, and several Stage I areas on both feet. She had recently traveled and had bought several pair of new shoes for her trip.

This week, Associate Medical Editor Joy Pape wraps up her discussion with R. Keith Campbell, MBA, at the 2015 ADA Sessions in Boston. In this segment, he talks about his 60+ years of experience as a type 1 diabetes patient and how what he has learned over the years influences his view of his diabetes today.

Simple screening tests will identify most secondary causes of hyperlipidemia.

This week, Associate Medical Editor Joy Pape continues her discussion with R. Keith Campbell, MBA, at the 2015 ADA Sessions in Boston. In this segment, he shares his advice with other healthcare providers in regards to how to help their patients. He advocates for patient education now to mitigate the expensive complications that could happen later.

This week, Associate Medical Editor Joy Pape meets with R. Keith Campbell, MBA, professor emeritus of Diabetes Care/Pharmacology at Washington State University at the 2015 ADA Sessions in Boston to discuss the latest interesting developments in diabetes care and management.

In this week's Homerun Slides, we look at the pro and contra arguments for forcing of early Insulin Therapy in patients with Type 2 Diabetes...

In this week’s Homerun Slides, we look at SGLT2 Inhibition as a novel treatment strategy for type 2 diabetes.

These subtle differences together may account for some of the increased cardiovascular risk in type 2 diabetes. The level of increased risk is the subject of much academic discussion. In large diabetic populations studied in the past, coronary risks were often found to be approximately doubled compared with non-diabetic groups, and the concept of diabetes as a coronary risk equivalent is almost embedded – type 2 patients who have not yet suffered a coronary event have a similar coronary risk as non- diabetic patients who have already had an event. The therapeutic corollary of this view is that all patients require equally intensive secondary prevention treatment.

Dyslipidemia in diabetes is usually the simplest cardiovascular risk factor to control. There are few patients whose lipid profile cannot be optimized, or at least markedly improved, with a combination of lifestyle interventions and single or combination drug therapy. The increasingly stringent targets recommended for high-risk patients, usually with pre-existing cardiovascular disease, proteinuria or both, are also attainable, but judicious combination therapy will be needed in some. There is persuasive evidence that low LDL levels maintained in the long term are associated with stabilization or even reversal of carotid and coronary atheroma, though we have yet to see the impressive intravascular ultrasound images correlate with event reduction in RCTs.